American International Group Decreased Murphy Oil (MUR) Holding; 3 Analysts Bullish ANI Pharmaceuticals, Inc. (ANIP)

April 17, 2018 - By Pete Kolinski

Murphy Oil Corporation (NYSE:MUR) Logo

American International Group Inc decreased Murphy Oil Corp (MUR) stake by 8.24% reported in 2017Q4 SEC filing. American International Group Inc sold 31,091 shares as Murphy Oil Corp (MUR)’s stock declined 17.46%. The American International Group Inc holds 346,222 shares with $10.75 million value, down from 377,313 last quarter. Murphy Oil Corp now has $4.94B valuation. The stock decreased 0.45% or $0.13 during the last trading session, reaching $28.54. About 202,907 shares traded. Murphy Oil Corporation (NYSE:MUR) has declined 2.02% since April 17, 2017 and is downtrending. It has underperformed by 13.57% the S&P500.

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. ANI Pharma had 20 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, September 28 by TH Capital. The stock of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has “Hold” rating given on Thursday, November 2 by Roth Capital. The rating was upgraded by Oppenheimer on Tuesday, July 19 to “Perform”. The rating was maintained by Canaccord Genuity on Thursday, December 7 with “Buy”. Canaccord Genuity maintained the shares of ANIP in report on Wednesday, August 9 with “Buy” rating. The stock of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has “Buy” rating given on Wednesday, September 2 by TheStreet. The company was upgraded on Monday, September 28 by Roth Capital. TH Capital maintained the shares of ANIP in report on Tuesday, August 4 with “Neutral” rating. The firm has “Outperform” rating given on Friday, August 5 by Oppenheimer. Standpoint Research downgraded the shares of ANIP in report on Tuesday, May 24 to “Hold” rating. See ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) latest ratings:

28/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $77 New Target: $82 Maintain
07/12/2017 Broker: Canaccord Genuity Rating: Buy New Target: $75.0 Maintain
02/11/2017 Broker: Roth Capital Rating: Hold New Target: $64.0 Maintain

The stock increased 0.32% or $0.19 during the last trading session, reaching $60.4. About 2,236 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 18.93% since April 17, 2017 and is uptrending. It has outperformed by 7.38% the S&P500.

Investors sentiment decreased to 1.09 in Q4 2017. Its down 0.60, from 1.69 in 2017Q3. It worsened, as 13 investors sold ANI Pharmaceuticals, Inc. shares while 43 reduced holdings. 23 funds opened positions while 38 raised stakes. 6.25 million shares or 0.89% less from 6.31 million shares in 2017Q3 were reported. Sei Invests owns 1,435 shares. The Illinois-based Northern Trust Corp has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Millennium Management has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Highland Capital Mgmt Ltd Partnership invested 0.01% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Pub Sector Pension Inv Board reported 0% stake. Metropolitan Life Ins New York stated it has 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Ameritas Invest Prtn has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Etrade Cap Management Limited Liability stated it has 23,832 shares or 0.05% of all its holdings. State Of Tennessee Treasury Department invested in 7,077 shares or 0% of the stock. Pnc Gp holds 1,083 shares. Thomson Horstmann Bryant Inc holds 0.17% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) or 20,101 shares. Prudential Fincl Inc owns 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 15,050 shares. Kbc Gp Nv reported 0.01% stake. Cortina Asset Mgmt Ltd stated it has 0.27% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Comerica Bancorporation has 9,167 shares.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $708.36 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It currently has negative earnings. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

Since March 1, 2018, it had 0 insider purchases, and 7 selling transactions for $9.84 million activity. Another trade for 28,652 shares valued at $1.77 million was made by Schrepfer Robert W on Thursday, March 1. On Thursday, March 8 the insider MARSHBANKS TRACY sold $4.05M. Marken James G. sold $258,640 worth of stock or 4,177 shares. $439,047 worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was sold by RAYNOR DANIEL. Shares for $1.47M were sold by PRZYBYL ARTHUR.

Among 14 analysts covering Murphy Oil Corporation (NYSE:MUR), 1 have Buy rating, 2 Sell and 11 Hold. Therefore 7% are positive. Murphy Oil Corporation had 45 analyst reports since July 22, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Monday, June 20 by Raymond James. The rating was initiated by Credit Agricole on Tuesday, December 15 with “Underperform”. The firm earned “Hold” rating on Tuesday, November 21 by Piper Jaffray. Morgan Stanley maintained the shares of MUR in report on Wednesday, October 18 with “Underweight” rating. The stock has “Hold” rating by Piper Jaffray on Tuesday, January 23. As per Tuesday, August 8, the company rating was maintained by Piper Jaffray. On Friday, February 12 the stock rating was maintained by Iberia Capital Partners with “Sector Perform”. Credit Suisse initiated Murphy Oil Corporation (NYSE:MUR) on Monday, December 11 with “Hold” rating. The firm has “Hold” rating given on Thursday, August 24 by Piper Jaffray. Barclays Capital maintained Murphy Oil Corporation (NYSE:MUR) on Friday, February 2 with “Equal-Weight” rating.

Since February 2, 2018, it had 0 insider purchases, and 1 sale for $965,516 activity. The insider Coleman Eugene T sold 33,435 shares worth $965,516.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.05, from 0.86 in 2017Q3. It is positive, as 47 investors sold MUR shares while 92 reduced holdings. 44 funds opened positions while 82 raised stakes. 156.61 million shares or 4.92% less from 164.72 million shares in 2017Q3 were reported. Hermes Investment Management Ltd reported 18,076 shares. Grace And White New York accumulated 312,156 shares. Origin Asset Mngmt Limited Liability Partnership reported 0.37% stake. Greenwich Wealth Mngmt Limited Liability Company has 0.14% invested in Murphy Oil Corporation (NYSE:MUR). Fiduciary Com invested in 13,047 shares. Northcoast Asset Ltd Co stated it has 57,339 shares or 0.16% of all its holdings. Cadence Management Limited holds 0.05% or 25,067 shares. 97,815 are held by Ameritas. Commonwealth State Bank Of Aus, Australia-based fund reported 91,562 shares. Federated Incorporated Pa reported 0.01% of its portfolio in Murphy Oil Corporation (NYSE:MUR). Moreover, Bank & Trust Of America De has 0% invested in Murphy Oil Corporation (NYSE:MUR) for 946,769 shares. Prudential Fincl reported 0.01% in Murphy Oil Corporation (NYSE:MUR). Jpmorgan Chase And stated it has 461,457 shares or 0% of all its holdings. Pacad Inv accumulated 8,400 shares or 0.06% of the stock. Pacific Heights Asset Management Ltd invested in 200,000 shares or 0.61% of the stock.

American International Group Inc increased National Oilwell Varco Inc (NYSE:NOV) stake by 12,943 shares to 190,915 valued at $6.88M in 2017Q4. It also upped Biomarin Pharmaceutical Inc (NASDAQ:BMRN) stake by 4,154 shares and now owns 17,177 shares. Edwards Lifesciences Corp (NYSE:EW) was raised too.

Analysts await Murphy Oil Corporation (NYSE:MUR) to report earnings on May, 2 after the close. They expect $0.24 earnings per share, up 500.00% or $0.30 from last year’s $-0.06 per share. MUR’s profit will be $41.52M for 29.73 P/E if the $0.24 EPS becomes a reality. After $0.08 actual earnings per share reported by Murphy Oil Corporation for the previous quarter, Wall Street now forecasts 200.00% EPS growth.

Murphy Oil Corporation (NYSE:MUR) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>